Tag: science
-
Clinical Development: Phases I to III
This is Part 5 in The Drug Development Playbook. In this article we move into clinical trials from phase I to III.
-
Hit Discovery and Lead Optimization – how teams turn a validated target into an actual drug candidate
This is Part 3 of The Drug Development Playbook. We answer the next question: how do you find molecules that not only hit that biology but can become safe, manufacturable medicines?
-
Disease Understanding and Target Identification: Picking the Biology Worth Backing
This is Part 2 of The Drug Development Playbook, an eight-part series on how medicines actually move from idea to patient use and how smarter decisions at each stage change outcomes.
-
How Genomics Is Changing Drug Target Selection in Big Pharma
The integration of human genetics in pharmaceutical research significantly enhances drug development. By prioritizing targets with genetic support, companies can improve trial efficacy and reduce risks. Utilizing genomics allows for better indication selection, safety predictions, and asset valuation. This strategic approach fosters innovation while addressing ethical considerations in clinical trials.
Aryan Kenia 